LRMR

Larimar Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website larimartx.com
Employees(FY) 26
ISIN US5171251003

Performance

-34.37%

-37.15%

-43.84%

-49.05%

-11.87%

YTD

+4.43%

Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of LRMR 2024-12-20

The Moving Average Score of 10 indicates a strong bearish sentiment, while the Oscillators Score of 53 suggests a neutral stance, and the overall Technical Score of 31 reinforces the bearish outlook. Collectively, these scores imply a predominantly negative sentiment in the stock, with limited bullish momentum.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LRMR

Stock Rank

Recent News & Updates

2024-12-16 18:20
Larimar Therapeutics announces initial data from OLE study of nomlabofusp(Yahoo Finance)
2024-12-15 18:00
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia(Yahoo Finance)
2024-12-15 18:00
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia(Globenewswire)
2024-11-17 18:00
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024(Globenewswire)
2024-10-30 07:00
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results(GlobeNewswire)
2024-10-29 19:00
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results(Globenewswire)
2024-10-17 08:53
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth(Simply Wall St.)
2024-09-19 07:00
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research(GlobeNewswire)
2024-09-18 19:00
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research(Globenewswire)
2024-08-27 08:00
Larimar Therapeutics to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-08-26 20:00
Larimar Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-07 07:00
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results(GlobeNewswire)
2024-08-06 19:00
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results(Globenewswire)
2024-07-30 09:25
Bullish Larimar Therapeutics Insiders Loaded Up On US$540.7k Of Stock(Simply Wall St.)
2024-05-30 16:05
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia(GlobeNewswire)
2024-05-30 04:05
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia(Globenewswire)
2024-05-21 23:25
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study(Zacks)
2024-05-20 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-05-20 16:05
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia(GlobeNewswire)
2024-05-20 04:05
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia(Globenewswire)
2024-05-10 06:28
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth(Simply Wall St.)
2024-05-09 07:00
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results(GlobeNewswire)
2024-05-09 01:55
LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-08 19:00
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results(Globenewswire)
2024-03-20 01:32
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks(Insidermonkey)
2024-03-14 16:05
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development(GlobeNewswire)
2024-03-14 09:53
LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-14 05:32
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results(Yahoo Finance)
2024-03-14 04:05
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development(Globenewswire)
2024-03-11 16:05
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia(GlobeNewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.